CN108066338A - 预防和治疗需氧菌与厌氧菌混合感染时的新型抗生素组合物及其制备方法 - Google Patents
预防和治疗需氧菌与厌氧菌混合感染时的新型抗生素组合物及其制备方法 Download PDFInfo
- Publication number
- CN108066338A CN108066338A CN201711433711.8A CN201711433711A CN108066338A CN 108066338 A CN108066338 A CN 108066338A CN 201711433711 A CN201711433711 A CN 201711433711A CN 108066338 A CN108066338 A CN 108066338A
- Authority
- CN
- China
- Prior art keywords
- sodium
- metronidazole
- cefuroxime sodium
- injection
- cefuroxime
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001148471 unidentified anaerobic bacterium Species 0.000 title claims abstract description 18
- 241001148470 aerobic bacillus Species 0.000 title claims abstract description 17
- 208000003322 Coinfection Diseases 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 29
- 230000002265 prevention Effects 0.000 title claims description 4
- 230000003115 biocidal effect Effects 0.000 title description 6
- 239000000203 mixture Substances 0.000 title description 5
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 claims abstract description 137
- 229960000534 cefuroxime sodium Drugs 0.000 claims abstract description 137
- 229960000282 metronidazole Drugs 0.000 claims abstract description 85
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 84
- 238000002347 injection Methods 0.000 claims abstract description 80
- 239000007924 injection Substances 0.000 claims abstract description 80
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 238000004806 packaging method and process Methods 0.000 claims abstract description 18
- 239000000243 solution Substances 0.000 claims description 86
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 76
- 230000001954 sterilising effect Effects 0.000 claims description 47
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 21
- 229920005549 butyl rubber Polymers 0.000 claims description 20
- 238000004659 sterilization and disinfection Methods 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 229910021645 metal ion Inorganic materials 0.000 claims description 18
- 230000000536 complexating effect Effects 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 239000002510 pyrogen Substances 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 239000012046 mixed solvent Substances 0.000 claims description 10
- 239000000049 pigment Substances 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 8
- 239000003610 charcoal Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims description 8
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000007974 sodium acetate buffer Substances 0.000 claims description 6
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 5
- 239000008215 water for injection Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 3
- 239000008139 complexing agent Substances 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 240000004307 Citrus medica Species 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 229910001873 dinitrogen Inorganic materials 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 15
- 229940087281 cefuroxime and metronidazole Drugs 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 239000012535 impurity Substances 0.000 description 28
- 230000008569 process Effects 0.000 description 23
- 239000000047 product Substances 0.000 description 19
- 239000000126 substance Substances 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 13
- 239000000463 material Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229960001668 cefuroxime Drugs 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 229920001971 elastomer Polymers 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 239000003182 parenteral nutrition solution Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 102000006635 beta-lactamase Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- -1 iron ion Chemical class 0.000 description 5
- BXWLVQXAFBWKSR-UHFFFAOYSA-N 2-methoxy-5-methylsulfonylbenzoic acid Chemical compound COC1=CC=C(S(C)(=O)=O)C=C1C(O)=O BXWLVQXAFBWKSR-UHFFFAOYSA-N 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 108090000204 Dipeptidase 1 Proteins 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 208000030961 allergic reaction Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 2
- HSCOLDQJZRZQMV-UHFFFAOYSA-N 1-Methyl-4-nitroimidazole Chemical compound CN1C=NC([N+]([O-])=O)=C1 HSCOLDQJZRZQMV-UHFFFAOYSA-N 0.000 description 2
- RSXWJXPKLRYMHW-UHFFFAOYSA-N 2-(2-methyl-4-nitroimidazol-1-yl)ethanol Chemical compound CC1=NC([N+]([O-])=O)=CN1CCO RSXWJXPKLRYMHW-UHFFFAOYSA-N 0.000 description 2
- UGPDZGBXWBKFMT-UHFFFAOYSA-N 2-[2-(2-methyl-5-nitroimidazol-1-yl)ethoxy]ethanol Chemical compound CC1=NC=C([N+]([O-])=O)N1CCOCCO UGPDZGBXWBKFMT-UHFFFAOYSA-N 0.000 description 2
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 description 2
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 description 2
- 241000606124 Bacteroides fragilis Species 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 241000206591 Peptococcus Species 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241001148134 Veillonella Species 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 2
- 229960002727 cefotaxime sodium Drugs 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- OUSLHGWWWMRAIG-FBCAJUAOSA-N (6r,7r)-7-[[(2z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(CO)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 OUSLHGWWWMRAIG-FBCAJUAOSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NVIAYEIXYQCDAN-UHFFFAOYSA-N 7-amino-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)C(N)C12 NVIAYEIXYQCDAN-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000005443 coulometric titration Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000009804 total hysterectomy Methods 0.000 description 1
- 229910021655 trace metal ion Inorganic materials 0.000 description 1
- 238000001771 vacuum deposition Methods 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
试验条件 | 3月 | 6月 | 9月 | 12月 | 18月 | 24月 | 30月 |
含量 | 99.2% | 99.0% | 98.7% | 98.2% | 97.9% | 97.2% | 96.3% |
总杂 | 0.12% | 0.14% | 0.18% | 0.28% | 0.35% | 0.49% | 0.62% |
序号 | 内毒素/热原水平 |
1 | <0.25EU |
2 | <0.25EU |
3 | <0.25EU |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711433711.8A CN108066338B (zh) | 2017-12-26 | 2017-12-26 | 抗生素组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711433711.8A CN108066338B (zh) | 2017-12-26 | 2017-12-26 | 抗生素组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108066338A true CN108066338A (zh) | 2018-05-25 |
CN108066338B CN108066338B (zh) | 2020-04-24 |
Family
ID=62155227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711433711.8A Active CN108066338B (zh) | 2017-12-26 | 2017-12-26 | 抗生素组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108066338B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111494314A (zh) * | 2020-06-01 | 2020-08-07 | 上海信谊金朱药业有限公司 | 一种盐酸氨溴索口服溶液及其制备方法 |
CN114652716A (zh) * | 2022-03-31 | 2022-06-24 | 中国农业科学院兰州畜牧与兽药研究所 | 地美硝唑在制备抗β-内酰胺类耐药性大肠杆菌药物中的应用 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775750A (en) * | 1983-07-29 | 1988-10-04 | Glaxo Group Limited | Process for preparing sodium cefuroxime |
CN1238911A (zh) * | 1999-01-07 | 1999-12-22 | 鹿瑞麟 | 一种生物制品防腐剂 |
EP1409492A1 (en) * | 2001-07-25 | 2004-04-21 | Lupin Limited | An improved method for preparation of cefuroxime axetil |
CN1830439A (zh) * | 2005-03-08 | 2006-09-13 | 巴里莫尔制药(通化)有限公司 | 一种甲硝唑冻干粉针剂的制备方法 |
CN101054386A (zh) * | 2006-11-12 | 2007-10-17 | 西南合成制药股份有限公司 | 头孢呋辛钠的合成方法 |
CN101475579A (zh) * | 2009-01-20 | 2009-07-08 | 广州白云山天心制药股份有限公司 | 一种稳定的头孢呋辛钠及其制备方法 |
CN101491502A (zh) * | 2008-10-24 | 2009-07-29 | 邢建荣 | 头孢呋辛钠冻干粉及其制备方法 |
CN102274167A (zh) * | 2011-07-20 | 2011-12-14 | 蚌埠丰原涂山制药有限公司 | 甲硝唑氯化钠注射液的制备方法 |
CN102525905A (zh) * | 2012-02-13 | 2012-07-04 | 河南天方华中药业有限公司 | 一种替硝唑氯化钠注射液及其制备方法 |
CN103044452A (zh) * | 2013-01-10 | 2013-04-17 | 潘行远 | 一种低水分、高稳定性的无菌头孢呋辛钠的制备方法 |
CN104774211A (zh) * | 2015-04-27 | 2015-07-15 | 四川制药制剂有限公司 | 注射用头孢呋辛钠的制备工艺 |
-
2017
- 2017-12-26 CN CN201711433711.8A patent/CN108066338B/zh active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775750A (en) * | 1983-07-29 | 1988-10-04 | Glaxo Group Limited | Process for preparing sodium cefuroxime |
CN1238911A (zh) * | 1999-01-07 | 1999-12-22 | 鹿瑞麟 | 一种生物制品防腐剂 |
EP1409492A1 (en) * | 2001-07-25 | 2004-04-21 | Lupin Limited | An improved method for preparation of cefuroxime axetil |
CN1830439A (zh) * | 2005-03-08 | 2006-09-13 | 巴里莫尔制药(通化)有限公司 | 一种甲硝唑冻干粉针剂的制备方法 |
CN101054386A (zh) * | 2006-11-12 | 2007-10-17 | 西南合成制药股份有限公司 | 头孢呋辛钠的合成方法 |
CN101491502A (zh) * | 2008-10-24 | 2009-07-29 | 邢建荣 | 头孢呋辛钠冻干粉及其制备方法 |
CN101475579A (zh) * | 2009-01-20 | 2009-07-08 | 广州白云山天心制药股份有限公司 | 一种稳定的头孢呋辛钠及其制备方法 |
CN102274167A (zh) * | 2011-07-20 | 2011-12-14 | 蚌埠丰原涂山制药有限公司 | 甲硝唑氯化钠注射液的制备方法 |
CN102525905A (zh) * | 2012-02-13 | 2012-07-04 | 河南天方华中药业有限公司 | 一种替硝唑氯化钠注射液及其制备方法 |
CN103044452A (zh) * | 2013-01-10 | 2013-04-17 | 潘行远 | 一种低水分、高稳定性的无菌头孢呋辛钠的制备方法 |
CN104774211A (zh) * | 2015-04-27 | 2015-07-15 | 四川制药制剂有限公司 | 注射用头孢呋辛钠的制备工艺 |
Non-Patent Citations (5)
Title |
---|
崔熙顺等: "注射用头孢呋辛钠稳定性的研究", 《药物研究》 * |
潘贤: "《药品质量监督与药品管理全书 上》", 31 August 1999 * |
陈壮生等: "注射用头孢呋辛钠粉针澄清度和颜色探讨", 《广东药学院学报》 * |
韩莹旻: "甲硝唑注射液与注射用头孢呋辛钠配伍稳定性考察", 《实用药物与临床》 * |
黄莹等: "注射用头孢呋辛钠质量统计分析", 《中国药学会第四届药物检测质量管理学术研讨会资料汇编》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111494314A (zh) * | 2020-06-01 | 2020-08-07 | 上海信谊金朱药业有限公司 | 一种盐酸氨溴索口服溶液及其制备方法 |
CN114652716A (zh) * | 2022-03-31 | 2022-06-24 | 中国农业科学院兰州畜牧与兽药研究所 | 地美硝唑在制备抗β-内酰胺类耐药性大肠杆菌药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108066338B (zh) | 2020-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102895181B (zh) | 注射用美洛西林钠的制备方法 | |
CN108066338A (zh) | 预防和治疗需氧菌与厌氧菌混合感染时的新型抗生素组合物及其制备方法 | |
CN102451154A (zh) | 硫酸奈替米星注射液及其制备方法 | |
CN103989630B (zh) | 盐酸莫西沙星氯化钠注射液及其制备方法 | |
CN108096198A (zh) | 预防和治疗需氧菌与厌氧菌混合感染时的新型抗菌药物组合物及其制备方法 | |
CN105147599B (zh) | 硫酸奈替米星注射液和制法 | |
CN103110640B (zh) | 一种注射用头孢唑肟钠和复方氨基酸注射液的药物组合物 | |
CN102755325B (zh) | 一种头孢西丁钠药物组合物、其粉针剂及其制备方法 | |
CN101904822B (zh) | 一种法罗培南钠冻干粉针及其制备方法 | |
CN102327270B (zh) | 一种β-内酰胺类复方抗生素组合物 | |
CN105640876B (zh) | 一种盐酸莫西沙星氯化钠注射液的制备工艺 | |
CN102688183B (zh) | 一种稳定的盐酸莫西沙星注射剂 | |
CN101574351A (zh) | 一种注射用头孢美唑制剂及其制备方法 | |
CN101225093B (zh) | 氨基糖苷类衍生物 | |
CN105213301B (zh) | 硫酸奈替米星注射液及其质控方法 | |
AU2012389714B2 (en) | Cocrystal of piperacillin sodium and sulbactam sodium and preparation method thereof, as well as pharmaceutical compositions containing same and uses thereof | |
WO2019233417A1 (zh) | 含达托霉素的喷雾干粉及其工业化制备方法 | |
CN102908312B (zh) | 抗乙肝病毒液体组合物 | |
CN1660116A (zh) | 一种新的硫酸头孢匹罗组合物及其制备方法 | |
CN102949397A (zh) | 注射用头孢噻肟钠和他唑巴坦钠制剂及其制备方法 | |
CN103027894A (zh) | 注射用头孢他啶组合物及其制备方法 | |
CN102697742B (zh) | 注射用盐酸头孢唑兰的制备工艺 | |
CN103432086B (zh) | 一种注射用培美曲塞二钠冻干粉针剂及其制备方法 | |
CN106366099B (zh) | 一种抗感染药物头孢曲松钠晶体化合物及其制备方法 | |
CN110893173A (zh) | 一种注射用头孢他啶粉针剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200306 Address after: 322399 Zhejiang city of Jinhua province Panan County town Xinshi Road No. 270 Applicant after: PAN'AN COUNTY DAODIPANYAO TRADITIONAL CHINESE MEDICINE Research Institute Address before: 322305 No. third, 30 building, No. 88, Yao Cheng Road, new town, Panan, Jinhua, Zhejiang, China. Applicant before: JINHUA ZHIJI DRUG TECHNOLOGY PARTNERSHIP ENTERPRISE (L.P.) |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210510 Address after: No.3-6, 1st floor, No.3 Factory building, No.100 Nanhai Avenue, Haikou Free Trade Zone, Hainan 570000 Patentee after: Hainan Jinkang Pharmaceutical Co.,Ltd. Address before: 322399 No. 270 Xinshi Road, Anwen Town, Pan'an County, Jinhua City, Zhejiang Province Patentee before: PAN'AN COUNTY DAODIPANYAO TRADITIONAL CHINESE MEDICINE Research Institute |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No.3-6, 1st floor, No.3 Factory building, No.100 Nanhai Avenue, Haikou Free Trade Zone, Hainan 570000 Patentee after: Hainan guangshengyu Pharmaceutical Co.,Ltd. Address before: No.3-6, 1st floor, No.3 Factory building, No.100 Nanhai Avenue, Haikou Free Trade Zone, Hainan 570000 Patentee before: Hainan Jinkang Pharmaceutical Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Antibiotic composition and its preparation method Effective date of registration: 20230810 Granted publication date: 20200424 Pledgee: Hainan Bank Co.,Ltd. Haikou Wuyuanhe Branch Pledgor: Hainan guangshengyu Pharmaceutical Co.,Ltd. Registration number: Y2023980051707 |